Program Announcement: Chris Rivera, “The State of Biotechnology,” February 17, 2022

Chris Rivera has spent more than 30 years in numerous leadership roles in the biotechnology industry, including Chairman, CEO and President of EMulate Therapeutics. Mr. Rivera is also the Chairman, President & Founder of Hapbee Technologies, Inc. (TSXV:HAPB), a publicly traded consumer wearable technology company.

Prior to EMulate, Mr. Rivera was the founder and CEO of Hyperion Therapeutics, which was acquired by Horizon Pharma in 2015; Senior Vice President (SVP) at Tercica, where he led the cross-licensing transaction between Tercica and Ipsen, and SVP at Genzyme Therapeutics, where he helped build and ran Genzyme’s US renal Commercial Operations, and helped launch Genzyme’s renal division globally. Prior to Genzyme, he helped build Cephalon and Centocor’s commercial infrastructures.

Mr. Rivera has extensive early stage and turnaround experience and success, in addition to a proven track record in building successful biotech companies. From 2009 – 2015, Mr. Rivera was the President & CEO of Life Science Washington (formerly Washington Biotechnology & Biomedical Association – WBBA), where he was responsible for building the biotechnology industry in Washington state. While at the WBBA, he oversaw one of Washington’s largest and fastest growing economic industries, including mentoring more than 400 life science start-up companies, and co-founding WINGS – Washington’s Medical Technology angel network.

He has also been recognized as a state and national leader through his appointments as; co-Chair for the (WA state) Governor’s life science and global health advisory committee, (WA state) Governor’s Higher Education Task Force, the Washington Global Health FundingCommission, and Chairman for the National Council of State Bioscience Associations.

Mr. Rivera holds a master’s degree from the University of Oklahoma Health Sciences Center; a bachelor’s degree from Northwestern Oklahoma State University; and studied marketing and management at the Albers Graduate School of Business and Economics at Seattle University.

Share thisEmail this to someoneShare on LinkedInTweet about this on TwitterShare on Facebook

Article Source: